Posters

POSTER SUBMISSION GUIDELINES

Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Posters should be submitted as a PowerPoint file. Presentations should incorporate illustrative materials such as tables, graphs, photographs, and large-print text. This content is not peer-reviewed. Submission is free.

SUBMIT YOUR ABSTRACT

Enter the following information to this Submission Form:

  • Poster Title
  • Your Name
  • Your Institution
  • Your Email
  • Abstract describing the poster

All submitted abstracts will be reviewed and decisions regarding acceptance will be made as abstracts are received. You will be notified within one week of receipt about acceptance. Further details and registration materials will be provided at that time. You do not have to be present in order to have a poster displayed. Only those abstracts approved by LabRoots may display posters at this event.

If accepted, you will also have the opportunity to record a 3-5 minute summary video for each poster. LabRoots will work with each individual to create these videos. Video links and email contact information will be included on each poster displayed.

Questions? Email Posters@LabRoots.com

LabRoots Policy

FEB 21 - 22 2018

Drug Discovery 2018

21 51 9973

Drug Discovery 2018 is now available On-Demand until May 22nd, 2018! 

Despite the rapid pace of scientific advances that garner a better understanding of a myriad of diseases on their molecular level, modern drug discovery is a long, complex process. As to be expected, the course of action for researching and developing new medicines is growing in difficulty and length. It is in this landscape that LabRoots is proud to announce its newest addition to the virtual event line up – Drug Discovery 2018!

Produced on a new, more robust platform, you can watch, learn and connect during this conference on mobile devices easier than ever before. Equipped with gamification and point system, you can now move around the entire event earning points for a chance to win one of LabRoots most popular shirts.

Industry leaders from around the world join together and discuss the advancements, challenges and successes of discovery and developing new medicines during this free, two-day event.

Topics discussed included:

  • GPCR Drug Discovery
  • Biomarkers in Early Stage Drug Development
  • Pharmacogenomics and Personalized Medicine
  • Emerging Trends

Continuing Education

By participating in this virtual event and watching webcast presentations, you can earn Free Continuing Education (CE) and/or Continuing Medical Education (CME) credits. To earn educational credits, you must view an entire presentation. Following the presentation, you must click on the educational credit link provided for that particular speaker and follow the required process. Once you have completed the process, you will receive a certificate for the educational credit.
 

Use #LRdrug to follow the conversation!


Speakers:
  • Chief, Program in MPE Molecular Pathological Epidemiology, Brigham and Women's Hospital, Professor of Pathology and Epidemiology, Harvard Medical School, Dana-Farber Cancer Institute
  • Biologist, CDRH/OIR/DMGP, U.S. Food and Drug Administration
  • Professor, University of Patras & Institute of Chemical Engineering FORTH/ICE-HT
  • Senior Vice President of Research and Development, NanoString Technologies
  • Associate Professor & Director, Center for Pharmacogenomics, University of Florida College of Pharmacy
  • Professor of Pediatrics, Ophthalmology, Optometry and Pharmacology, Université de Montréal, Adjunct Professor of Pharmacology, McGill University, Université de Montréal
  • Assistant Professor of Microbiology, Immunology, & Tropical Medicine at The George Washington University
  • Deputy Chairman and Associate Professor in the Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center
  • Director, Pharmacogenomics at NorthShore University HealthSystem
  • Postdoctoral Research Fellow, The Scripps Research Institute
  • Chief Scientific Officer, Vaccibody AS
  • Associate-Professor, Pharmaceutical Sciences, Midwestern University
  • Professor, Associated Laboratory Director, Saint-Luc University Hospital, Brussels, Belgium
  • Grollman-Glick Professor of Pharmaceutical Sciences, Director, Computer-Aided Drug Design Center, University of Maryland School of Pharmacy
  • Professor of Pharmacology, Director of Molecular Pharmacology, Vanderbilt Center for Neuroscience Drug Discovery
  • Michael Hooker Distinguished Professor, Department of Pharmacology and Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy
  • Business Development Manager at AroCell AB
  • Chief Scientific Officer, 3D-2drug LLC
  • Assistant Professor of Biochemistry and Molecular Medicine, GW School of Medicine and Health Sciences
  • Professor and Department Chair, Chemical Engineering, Art Zafiropoulo Chair in Engineering, Affiliated Faculty, Bioengineering, Northeastern University, College of Engineering

Show Resources
Agenda
  • FEB 21, 2018 06:00 AM PST
    Speaker: Alejandro Villagra, PhD
  • FEB 21, 2018 07:30 AM PST
    Speaker: Shuji Ogino, MD, PhD, MS
  • FEB 21, 2018 09:00 AM PST
    Speaker: Martin Shaw
  • FEB 21, 2018 09:00 AM PST
    Speaker: Matthew Eddy, PhD
  • FEB 21, 2018 10:30 AM PST
    Annette Gilchrist, PhD
    Associate-Professor, Pharmaceutical Sciences, Midwester...
    Martin Shaw
    Business Development Manager at AroCell AB
    Thomas Webster, PhD
    Professor and Department Chair, Chemical Engineering, A...
  • FEB 21, 2018 10:30 AM PST
    Speaker: Katherine Chiappinelli, PhD
  • FEB 21, 2018 12:00 PM PST
    Speaker: Colleen Niswender, PhD
  • FEB 21, 2018 12:00 PM PST
    Speaker: Larisa Cavallari, Pharm. D.
  • FEB 21, 2018 01:30 PM PST
    Speaker: Alexander MacKerell, PhD
  • FEB 21, 2018 01:30 PM PST
    Speaker: Sophia Antimisiaris, PhD
  • FEB 22, 2018 06:00 AM PST
    Speaker: Agnete Fredriksen, MSc, PhD
  • FEB 22, 2018 06:00 AM PST
    Speaker: Damien Gruson, PhD
  • FEB 22, 2018 07:30 AM PST
    Speaker: Janaki Veeraraghavan, PhD
  • FEB 22, 2018 09:00 AM PST
    Speaker: Mark Dunnenberger, PharmD
  • FEB 22, 2018 09:00 AM PST
    Sponsored By: Nanostring Technologies
    Michael Davies, MD, PhD
    Deputy Chairman and Associate Professor in the Departme...
    Joseph Beechem, PhD
    Senior Vice President of Research and Development, Nan...
  • FEB 22, 2018 10:30 AM PST
    Speaker: Bryan L. Roth, MD, PhD
  • FEB 22, 2018 10:30 AM PST
    Speaker: Sylvain Chemtob, MD, PhD, FRCPC, FAAP, FCAHS
  • FEB 22, 2018 12:00 PM PST
    Speaker: Thomas Webster, PhD
  • FEB 22, 2018 12:00 PM PST
    Speaker: Sid Topiol, PhD
  • FEB 22, 2018 01:30 PM PST
    Speaker: Annette Gilchrist, PhD
  • Pharmacogenomics and Personalized Medicine
  • FEB 21, 2018 06:00 AM PST
    Speaker: Alejandro Villagra, PhD
  • FEB 21, 2018 07:30 AM PST
    Speaker: Shuji Ogino, MD, PhD, MS
  • FEB 21, 2018 10:30 AM PST
    Annette Gilchrist, PhD
    Associate-Professor, Pharmaceutical Sciences, Midwester...
    Martin Shaw
    Business Development Manager at AroCell AB
    Thomas Webster, PhD
    Professor and Department Chair, Chemical Engineering, A...
  • FEB 21, 2018 12:00 PM PST
    Speaker: Larisa Cavallari, Pharm. D.
  • FEB 22, 2018 06:00 AM PST
    Speaker: Agnete Fredriksen, MSc, PhD
  • FEB 22, 2018 09:00 AM PST
    Speaker: Mark Dunnenberger, PharmD
  • Biomarkers in Early Stage Drug Development
  • FEB 21, 2018 09:00 AM PST
    Speaker: Martin Shaw
  • FEB 22, 2018 07:30 AM PST
    Speaker: Janaki Veeraraghavan, PhD
  • FEB 22, 2018 09:00 AM PST
    Sponsored By: Nanostring Technologies
    Michael Davies, MD, PhD
    Deputy Chairman and Associate Professor in the Departme...
    Joseph Beechem, PhD
    Senior Vice President of Research and Development, Nan...
  • GPCR Drug Discovery
  • FEB 21, 2018 09:00 AM PST
    Speaker: Matthew Eddy, PhD
  • FEB 21, 2018 12:00 PM PST
    Speaker: Colleen Niswender, PhD
  • FEB 21, 2018 01:30 PM PST
    Speaker: Alexander MacKerell, PhD
  • FEB 22, 2018 10:30 AM PST
    Speaker: Bryan L. Roth, MD, PhD
  • FEB 22, 2018 12:00 PM PST
    Speaker: Sid Topiol, PhD
  • FEB 22, 2018 01:30 PM PST
    Speaker: Annette Gilchrist, PhD
  • Emerging Trends
  • FEB 21, 2018 10:30 AM PST
    Speaker: Katherine Chiappinelli, PhD
  • FEB 21, 2018 01:30 PM PST
    Speaker: Sophia Antimisiaris, PhD
  • FEB 22, 2018 06:00 AM PST
    Speaker: Damien Gruson, PhD
  • FEB 22, 2018 10:30 AM PST
    Speaker: Sylvain Chemtob, MD, PhD, FRCPC, FAAP, FCAHS
  • FEB 22, 2018 12:00 PM PST
    Speaker: Thomas Webster, PhD
Speakers

  • Shuji Ogino, MD, PhD, MS
    Chief, Program in MPE Molecular Pathological Epidemiology, Brigham and Women's Hospital, Professor of Pathology and Epidemiology, Harvard Medical School, Dana-Farber Cancer Institute
    Biography
      Dr. Shuji Ogino is Professor (of Pathology and Epidemiology) at Dana-Farber Cancer Institute, Brigham and Women's Hospital (BWH), Harvard Medical School, and Harvard T.H. Chan School of Public Health; the founding Chief of Program in MPE Molecular Pathological Epidemiology at BWH; and an Associate Member of Broad Institute of MIT and Harvard. Dr. Ogino has been developing the transdisciplinary science "Molecular Pathological Epidemiology (MPE)", which bridges and integrates molecular biologic and population health sciences. Since 2013, he has been the Chairperson for The International MPE Meeting Series, and the Fourth International MPE Meeting will be held in Boston in 2018 (www.mpemeeting.org). Dr. Ogino has received numerous awards and honors, including CAP Foundation Scholars Award; USCAP Ramzi Cotran Young Investigator Award; Executive Officer's Award and Meritorious Service Award from AMP; recognitions of "Most Influential Scientific Minds" in 2014, and "Highly Cited Researcher" in 2015, 2016, and 2017 by Thomson Reuters and Clarivate Analytics; elected membership in ASCI; membership of FASEB Excellence in Science Award Committee; and membership of various NIH study sections, most notably NCI R35 Outstanding Investigator Award (OIA) Special Emphasis Panel in 2016. Dr. Ogino has been a recipient of prestigious NCI R35 OIA grant, which represent 7-year funding for me to pursue paradigm-shifting high impact research.
    • Janaki Veeraraghavan, PhD
      Biologist, CDRH/OIR/DMGP, U.S. Food and Drug Administration
      Biography
        Janaki Veeraraghavan graduated from University of Texas Health Science Center at San Antonio with Ph.D. in Biochemistry. Her thesis investigated the role of Growth factors in tumor growth and the impact of Mismatch repair protein mutations on cell cycle progression. Her post-doctoral fellowship at University of Rochester focused on sequence expansion from DNA replication errors, following which she joined a biotechnology startup. Her experience includes development/validation, from target discovery to Phase II clinical trial, of antibody therapeutics for autoimmune disorders and cancer immunotherapy as well as identification and development of response predictive biomarkers and associated test systems. In the last 3 years, as an FDA review staff in office of in vitro diagnostic and Radiological health at CDRH, she has been involved in the review of companion and complementary diagnostic devices for oncology indications with focus on devices to support immunotherapy and checkpoint inhibitors and update of policy guidelines for review of immunohistochemistry devices.
      • Sophia Antimisiaris, PhD
        Professor, University of Patras & Institute of Chemical Engineering FORTH/ICE-HT
        Biography
          Sophia G. Antimisiaris received her B.Pharm (1984) and Ph.D in Pharmaceutics (1988) from Athens University, Greece. She worked as a Post-doc research assistant in the School of Pharmacy of the University of South California, Los Angeles for 2 years (1989-1990), and then became a Lecturer of Pharmaceutical Technology in the University of Patras in Greece, where she became the head of the Laboratory of Pharmaceutical Technology (from 2002) and a full Professor in 2009. During a sabbatical leave from Patras, she worked on Liposome Technologies for Advanced Drug Delivery applications as a Visiting Professor in the School of Pharmacy, University of London, group of Prof. Gregory Gregoriadis from 1992 till 1993. From 2006, after invitation, she is a collaborating member of the Institute of Chemical Engineering of the Foundation of Research and Technology Hellas (FORTH), the largest research Institute in Greece. SGA's research group focuses on the development of liposomal nanomedicines for controlled and/or targeted drug delivery. She has received funding from National and European sources (FP6, INTERREG, Marie Curie, FP7), as well as Industry. Her group was responsible for the development of advanced liposomal formulations in several large collaborating European projects (SHIVA, Euro-PhD in Advanced Drug Delivery Systems, NAD), as well as numerous National research programs. She is the main author of more than 100 peer-reviewed papers and more than 25 book chapters and review articles. She has mentored more than 25 MSc students and 11 PhD Thesis and participated in the advisory committees of more than 50 Post-graduate degrees in Greece and other countries. She is a member of AAPS, CRS (& CRS-Greek Chapter), ILS and other National and International Scientific Societies, and inventor of 5 Greek, 1 European, 1 US and 1 World patent.
        • Joseph Beechem, PhD
          Senior Vice President of Research and Development, NanoString Technologies
          Biography
            Since April 2012, Joe Beechem has led NanoString Technologies in its pursuit of next-generation immune-oncology. With deep expertise in genetic analysis, sequencing, and research, Dr. Beechem has directed the design and development of multiple genetic analysis technologies including various sequencing platforms.
          • Larisa Cavallari, Pharm. D.
            Associate Professor & Director, Center for Pharmacogenomics, University of Florida College of Pharmacy
            Biography
              Larisa H. Cavallari, Pharm.D., is an Associate Professor and Associate Chair in the Department of Pharmacotherapy and Translational Research, Director of Center for Pharmacogenomics, and Associate Director of the Personalized Medicine Program at the University of Florida. She received her Pharm.D. degree from the University of Georgia, followed by a pharmacy practice residency at the VA Medical Center in Memphis, Tennessee and a fellowship in cardiovascular pharmacogenomics at the University of Florida. Her research involves discovery of genetic associations with drug response and their translation into clinical practice. Her research is currently funded by the NIH and FDA in addition to receiving industry support.
            • Sylvain Chemtob, MD, PhD, FRCPC, FAAP, FCAHS
              Professor of Pediatrics, Ophthalmology, Optometry and Pharmacology, Université de Montréal, Adjunct Professor of Pharmacology, McGill University, Université de Montréal
              Biography
                Sylvain Chemtob is a reputed neonatal pharmacologist and physiologist, with expertise on mechanisms implicated in ischemic retinopathies and other conditions involving inflammation including preterm labor. He has also initiated a new technology to develop peptidomimetic drugs that target membrane receptors; some compounds are licensed to industry, and one which successfully completed Phase Ib clinical trial is Phase II-ready (PDC Biotech). His seminal work also triggered the approval (EMEA [2004], FDA [2006]) of new therapies for closure of ductus arteriosus, which is now standard of care. Sylvain Chemtob is author of over 270 articles reported in major journals, as well as inventor of 10 patents. He has trained so far 46 graduate students and 29 post-graduate fellows (MDs and PhDs). He has received numerous awards and is a member of the Canadian Academy of Health Sciences. He holds a Canada Research Chair (Vision Science) and the Leopoldine Wolfe Chair in Translational Research in age-related macular degeneration at Universite de Montreal.
              • Katherine Chiappinelli, PhD
                Assistant Professor of Microbiology, Immunology, & Tropical Medicine at The George Washington University
                Biography
                  Katherine Bakshian Chiappinelli, Ph.D., joined the GW Department of Microbiology, Immunology and Tropical Medicine University in 2017 as an Assistant Professor.Dr. Chiappinelli graduated with a B.S. in Biology and Music from Haverford College in 2007 and received her Ph.D. in Developmental, Regenerative, and Stem Cell Biology from Washington University in St. Louis under the supervision of Dr. Paul Goodfellow in 2012. Dr. Chiappinelli pursued postdoctoral studies at Johns Hopkins University with Dr. Stephen Baylin investigating the epigenetic control of immune signaling in cancer cells. Her research focuses on how epigenetic therapies can be used against cancers, specifically in the context of arming the host immune system to fight cancer cells.
                • Michael Davies, MD, PhD
                  Deputy Chairman and Associate Professor in the Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center
                  Biography
                    Dr. Davies is the Deputy Chairman and associate professor in the Department of Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center, with joint appointments in the Departments of Systems Biology and Translational Molecular Pathology. Dr. Davies is a physician-scientist whose research utilizes integrated approaches to study the regulation and clinical significance of oncogenic signaling networks in cancer, particularly in therapeutic resistance and in the molecular pathogenesis of brain metastases. Dr. Davies has been the principal investigator of both individual and team science peer-reviewed grants from several organizations, including the National Cancer Institute (NCI), the American Society of Clinical Oncology (ASCO), the Melanoma Research Alliance, and the Melanoma Research Foundation. He has served as the principal investigator of several clinical trials for patients with metastatic melanoma, and has authored or co-authored >100 manuscripts in peer-reviewed journals including Cell, Cancer Cell, Science, Cancer Discovery, Cancer Research, and Clinical Cancer Research. Dr. Davies is a member of the American Society for Clinical Investigation, the Melanoma Research Foundation Breakthrough Consortium, and the International Melanoma Working Group.
                  • Mark Dunnenberger, PharmD
                    Director, Pharmacogenomics at NorthShore University HealthSystem
                    Biography
                      Dr. Dunnenberger is Director of Pharmacogenomics in the Center for Molecular Medicine at NorthShore University HealthSystem (NorthShore), and leads the various clinical pharmacogenomics implementation projects within the Center for Personalized Medicine. The goal of these projects is to improve the care and health outcomes of NorthShore University HealthSystem patients through pharmacogenomics-based strategies. He joined NorthShore in 2014. Dr. Dunnenberger leads the Pharmacogenomics Clinic, which serves as part of a system-wide initiative building upon the health system's strong foundation in genetics and molecular medicine. The Clinic is among only a few across the country, and the first of its kind in the Chicagoland area that pre-emptively screens patients for responses to medications based on genetic makeup. His clinical expertise and research interests include translating pharmacogenomics into clinical practice, developing information technology solutions for delivering genetic information to both clinicians and patients in a practical manner, and evaluating methods for educating healthcare professionals about pharmacogenetics Dr. Dunnenberger has co-authored sixteen original publications, including several CPIC guidelines. He earned his PharmD from the University of Tennessee Health Science Center College of Pharmacy in 2012. He completed a PGY1 Pharmacy Practice Residency at Mission Hospital in Asheville, North Carolina, and a PGY2 Clinical Pharmacogenetics Residency in the Department of Pharmaceutical Sciences at St. Jude Children's Research Hospital in Memphis, Tennessee.
                    • Matthew Eddy, PhD
                      Postdoctoral Research Fellow, The Scripps Research Institute
                      Biography
                        Matthew Eddy received his PhD in physical chemistry from the Massachusetts Institute of Technology in the laboratory of Professor Robert Griffin. During his PhD, Dr. Eddy developed new approaches for using nuclear magnetic resonance (NMR) in the solid state to determine structures of membrane proteins in cellular-like environments. Following his PhD, Dr. Eddy joined the laboratories of Professors Raymond Stevens and Kurt Wüthrich at The Scripps Research Institute as an American Cancer Society Postdoctoral Fellow. As a postdoctoral fellow, Dr. Eddy used an integrative structural biology approach to study the structures, conformational dynamics, and functions of human G protein-coupled receptors (GPCRs), focusing on the application of nuclear magnetic resonance to improve our understanding of GPCR allosteric function.
                      • Agnete Fredriksen, MSc, PhD
                        Chief Scientific Officer, Vaccibody AS
                        Biography
                          Agnete B. Fredriksen is Co-Founder and joined Vaccibody in 2007. She holds a MSc, PhD from Institute of Immunology, Rikshospitalet Medical Center in Oslo where she designed and developed the first Vaccibody vaccine molecules. She received the King's Gold Medal for her PhD thesis describing Vaccibodies. Her focus is on cancer vaccines from idea to clinical development. Previous employment includes Affitech AS and Medinnova AS. Agnete is author on numerous scientific papers in the field of immunology, immunotherapy and vaccines. Inventor on several patents in the field of immunotherapy. She is board member for the BIA programme of NRC stimulating research in the Norwegian industry.
                        • Annette Gilchrist, PhD
                          Associate-Professor, Pharmaceutical Sciences, Midwestern University
                          Biography
                            An Associate Professor with Midwestern University, and adjunct faculty member at Northwestern University Dr. Annette Gilchrist has a PhD in Immunology from the University of Connecticut Health Center and a MS in Biochemistry from the University of Connecticut. Previously, she was with Cue Biotech and Caden Biosciences, companies she co-founded that focused on identifying modulators of G protein-coupled receptors (GPCRs) utilizing novel approaches (US Patent Numbers 6,559,128; 7,208,279; and 7,294,472). Her current research is on allosteric and functionally selective modulators of GPCRs with her primary receptors of interest being the chemokine receptor CCR1 and the recently deorphanized FFAR2. She is an International Editor for the British Journal of Clinical Pharmacology and recently served as a guest co-editor for a Frontiers in Endocrinology Bone Research themed issue on "Chemokines and Bone".
                          • Damien Gruson, PhD
                            Professor, Associated Laboratory Director, Saint-Luc University Hospital, Brussels, Belgium
                            Biography
                              Professor Damien Gruson was awarded his degree of Pharmacist and later of Specialist in Laboratory Medicine from the Catholic University of Louvain, Brussels, Belgium. He joined the Department of Laboratory Medicine of the St-Luc University Hospital in 2008. He is now associated laboratory director and leading Endocrine Biology. He is also member of the research unit on Endocrinolgy Diabetes and Nutrition of the Catholic University of Louvain. Pr. D. Gruson has published numerous articles in several international peer-reviewed journals. Pr. D. Gruson is a member of the committee on distance learning of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), of the IFCC task force for young scientists (Chair between 2010 and 2012 and now consultant), a member of the division of Endocrinology of the American Association of Clinical Chemistry. Pr. D. Gruson is also a Fellow of the European Society of Cardiology.
                            • Alexander MacKerell, PhD
                              Grollman-Glick Professor of Pharmaceutical Sciences, Director, Computer-Aided Drug Design Center, University of Maryland School of Pharmacy
                              Biography
                                Alex MacKerell received a Ph.D. in Biochemistry in 1985 from Rutgers University, which was followed by postdoctoral fellowships in the Department of Medical Biophysics, Karolinska Intitutet, Stockholm, Sweden and the Department of Chemistry, Harvard University. In 1992 he assumed his faculty position in the School of Pharmacy, University of Maryland where he is currently the Grollman-Glick Professor of Pharmaceutical Sciences and the Director of University of Maryland Computer-Aided Drug Design Center. MacKerell is also Co-founder and CSO of SilcsBio LLC, a biotech company in the area of computer-aided drug design.
                              • Colleen Niswender, PhD
                                Professor of Pharmacology, Director of Molecular Pharmacology, Vanderbilt Center for Neuroscience Drug Discovery
                                Biography
                                  Colleen Niswender is a Professor of Pharmacology at Vanderbilt University and the Director of Molecular Pharmacology for the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD). During her graduate training and initial postdoctoral studies, she worked to elucidate the molecular mechanisms regulating the RNA editing of AMPA and serotonin receptors. She then pursued postdoctoral studies focused on the genetic regulation of Protein Kinase A using recombinant mice at the University of Washington. Her work at the VCNDD involves assay development, high throughput screening and characterization of novel G protein-coupled receptor allosteric ligands both in vitro and in vivo. She has been involved in multiple small molecule discovery projects to search for and characterize novel allosteric modulators of various metabotropic glutamate (mGlu) and muscarinic receptors. This work has resulted in the progression of an M1 muscarinic receptor positive allosteric modulator, discovered at Vanderbilt, through Investigational New Drug Application studies and into clinical development for the treatment of cognitive deficits in Alzheimer's disease and schizophrenia. During the past five years, Dr. Niswender has established a new research program focused on the therapeutic potential of mGlu and muscarinic receptor allosteric modulators for the treatment of various neurodevelopmental disorders, including Rett syndrome, MECP2 Duplication syndrome, and Neurofibromatosis Type 1.
                                • Bryan L. Roth, MD, PhD
                                  Michael Hooker Distinguished Professor, Department of Pharmacology and Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy
                                  Biography
                                    Bryan L. Roth MD, PhD is the Michael Hooker Distinguished Professor of Pharmacology at the University of North Carolina Chapel Hill School of Medicine. Dr. Roth received his MD and PhD (Biochemistry) from St. Louis University in 1983 and subsequently training in pharmacology (NIH), molecular biology and psychiatry (Stanford) . Dr. Roth has published more than 400 papers in the general area of the molecular pharmacology of drug actions, including a large number of papers published in Science, Nature and Cell over the past decade. Dr. Roth has more than 40 patents and has founded 2 companies. Dr. Roth has been elected to the National Academy of Medicine of the National Academy of Sciences and has received many honors including the Goodman and Gilman Award for Receptor Pharmacology (ASPET; 2016), the PhRMA Foundation Excellence in Pharmacology Award, and a NARSAD Distinguished Investigator Award. Dr. Roth also given many endowed lectures including the Goodman, Koppyani, Strongwater, Niznik, Swammerdam, Lowenthal, S.G. Fergusson, Chauncy Leake and Philip S. Portoghese Lectures. Dr. Roth has also been named the 2018 IUHPAR Lecturer in Analytical Pharmacology (IUPHAR), the 2017 Martin S. Rodbell Lecturer and the inaugural 2017 Elliot Saul Vessell Visiting Professor. Dr. Roth has also been named a Thompson Reuters 'Highly Cited Scientist' in Pharmacology and in Biology and Biochemistry.
                                  • Martin Shaw
                                    Business Development Manager at AroCell AB
                                    Biography
                                      Between 1994-2015 he worked at EKF Diagnostics in Wales (formerly Argutus Medical) where he introduced and promoted a wide range of novel kidney and liver tests, including important biomarkers that are now being evaluated by the IMI (Innovative Medicines Initiative) and FDA as qualified for use in toxicological testing. He developed strong relationships with hospitals, clinical research organizations and pharmaceutical companies, including AstraZeneca, Sanofi Aventis, Pfizer, Novartis, Merck, Glaxo Smith Kline and Johnson and Johnson. From 1975-1992 Martin Shaw filled many technical and marketing roles at Pharmacia Diagnostics (now Thermo-Fisher). He and his coworkers developed and introduced the first commercial tests for neonatal hypothyroidism, celiac disease, and a range of novel biomarkers to monitor allergy and inflammation. Bringing testing close to the patient is important and Martin brings this experience from being Marketing Manager at Magnasense Technologies, Finland, where he introduced and promoted a novel point-of-care test system based on magnetically labelled antibodies. Martin has published several peer-reviewed articles on biomarkers and presented at many scientific congresses, including being guest speaker at the FDA.
                                    • Sid Topiol, PhD
                                      Chief Scientific Officer, 3D-2drug LLC
                                      Biography
                                        Sid Topiol is the founder and CSO of 3D-2drug LLC, a collaborative research organization incubating drug discovery projects. 3D-2drug is rooted in the deployment of protein structure/function information into novel and efficient drug discovery opportunities. Sid received his B.S. from CCNY and his Ph.D. from NYU. He trained as a theoretical quantum chemist. He post-docked at Northwestern with Mark Ratner and Arthur Frost, and at Carnegie-Mellon with John Pople (Noble laureate.) He has held various academic affiliations through his career including The Mount Sinai School of Medicine, New Jersey Institute of Technology and Stevens Institute of Technology. He has spent over 20 years in Pharma, starting with Berlex followed by Sandoz/Novartis and then Lundbeck. He has worked on all aspects of Computer Aided Drug Design in interdisciplinary project environments. In 2010 he formed 3D-2Drug. He serves on the Editorial Board of Drug Development Research.
                                      • Alejandro Villagra, PhD
                                        Assistant Professor of Biochemistry and Molecular Medicine, GW School of Medicine and Health Sciences
                                        Biography
                                          Dr. Villagra's areas of expertise are epigenetics and tumor immunology. During his early scientific career, he explored different aspects of epigenetic regulation including DNA methylation, ATP-dependent chromatin remodeling complexes, histone acetyltranferases and histone deacetylases. His study models have been diverse and have included myogenic and osteoblastic differentiation, gene regulation of immune-related pathways and tumor immunology. Over the last several years, his group has focused on the study of the role of different epigenetic modifiers in the modulation of anti-tumor immune responses, assigning a special emphasis to the identification of potential therapeutic agents to improve immunotherapy. Dr. Villagra's group experimental approaches have important translational components, which allow them the possibility to extend their research into the clinical area. These particular characteristics help provide continuous scientific feedback and keep goals focused on relevant biomedical aspects of research.
                                        • Thomas Webster, PhD
                                          Professor and Department Chair, Chemical Engineering, Art Zafiropoulo Chair in Engineering, Affiliated Faculty, Bioengineering, Northeastern University, College of Engineering
                                          Biography
                                            Thomas J. Webster's (H index: 80, Google Scholar) degrees are in chemical engineering from the University of Pittsburgh (B.S., 1995) and in biomedical engineering from Rensselaer Polytechnic Institute (M.S., 1997; Ph.D., 2000). Prof. Webster is the current director of the Nanomedicine Laboratories (currently at 23 members) and has completed extensive studies on the use of nanophase materials in medicine. He pioneered the use of nanomaterials to increase tissue growth, inhibit infection, and decrease inflammation. He was appointed Department Chair of Chemical Engineering at Northeastern University in 2012 in which the Department recently broke the record for the fastest increase in ranking over a five year period from the U.S. News and World Report. In his 17 years in academics, Prof. Webster has graduated/supervised over 149 visiting faculty, clinical fellows, post-doctoral students, and thesis completing B.S., M.S., and Ph.D. students. To date, his lab group has generated over 13 textbooks, 68 book chapters, 376 invited presentations, at least 503 peer-reviewed literature articles and/or conference proceedings, at least 767 conference presentations, and 42 provisional or full patents. His research has led to the formation of 12 companies with 4 FDA approved nanomedicine products. He is the founding editor-in-chief of the International Journal of Nanomedicine (the first open-access, international journal in nanomedicine which has a 5-year impact factor of 5.03). Prof. Webster currently directs or co-directs several centers in the area of biomaterials: The Center for Natural and Tropical Biomaterials (Medellin, Colombia), The Center for Pico and Nanomedicine (Wenzhou China), and The International Materials Research Center (Soochow, China). He was named the Art Zafiropoulo Chair at Northeastern University for his contributions to nanomedicine in 2013. Prof. Webster has received numerous honors including but not limited to: 2012, Fellow, American Institute for Medical and Biological Engineering (AIMBE, representing the top 2% of all medical and biological engineers); 2013, Fellow, Biomedical Engineering Society; 2015, Wenzhou 580 Award; 2015, Zheijang 1000 Talent Program; 2016, International Materials Research Chinese Academy of Science Lee-Hsun Lecture Award; 2016, International College of Fellows, Biomaterials Science and Engineering; and 2016, Acta Biomaterialia Silver Award. He also served as the President of the U.S. Society For Biomaterials. He has appeared on BBC, NBC, ABC, Fox News, the Weather Channel, the Discovery Channel, and the recent special 'Year Million' TV series on National Geographic talking about the future of medicine and science.
                                          Sponsored By

                                          For information on becoming a sponsor or exhibitor, please click here.


                                          Continuing Education (CME/CE/CEU) Credits

                                          The speakers below have been approved for CME, CE, or CEU credits. To redeem your credits, locate the presentation you watched and click on the CME/CE/CEU buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here


                                          Committee

                                          To download the Program Committee brochure here.


                                          • Annette Gilchrist

                                            An Associate Professor with Midwestern University, and adjunct faculty member at Northwestern University Dr. Annette Gilchrist has a PhD in Immunology from the University of Connecticut Health Center and a MS in Biochemistry from the University of Connecticut. Previously, she ...

                                            See more See less
                                          • Martin Shaw

                                            Between 1994-2015 he worked at EKF Diagnostics in Wales (formerly Argutus Medical) where he introduced and promoted a wide range of novel kidney and liver tests, including important biomarkers that are now being evaluated by the IMI (Innovative Medicines Initiative) and FDA as ...

                                            See more See less
                                          Help

                                          General LabRoots Questions

                                          For bugs, spam, technical support or questions please call +1-714-463-4673 or email support@labroots.com  
                                          Contact us

                                          Virtual Events and Webinars

                                          Supported Configurations

                                          • Operating System Internet Explorer Firefox Chrome Safari
                                            Vista IE8+ FF10+ Chrome15+
                                            Windows 7 IE8+ FF10+ Chrome15+
                                            Windows 8 IE10 FF10+ Chrome15+
                                            Mac OS X   FF10+ Chrome15+ Safari5.1+
                                          • Cookie settings: session cookies enabled
                                          • Browser configuration must have JavaScript enabled
                                          • Adobe Flash player 10.2 or later

                                          To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

                                          Internet Connection

                                          • A minimum of 100Kbps is recommended for audio-only events
                                          • A minimum of 300Kbps is recommended for speaker on-video events

                                          Computer Equipment

                                          • Screen Resolution: Minimum 1024x768
                                          • Video Card: 65,000 colors minimum
                                          • Sound card and speakers (or headphones) for hearing webcast in full format
                                          • Audio Card: 16-bit minimum
                                          • RAM: 512MB of free RAM

                                          Firewall Protocol

                                          • HTTP on port 80 or HTTPS on port 443
                                          • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
                                          • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

                                          Work-At-Home Attendees

                                          • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

                                          For A Seamless Experience

                                          When using a mobile device, FREE Mobile Apps are available:

                                          - For viewing Webinars:

                                          - For viewing Virtual Events

                                          Attendee Guide

                                          • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

                                          Virtual Event and Webinar Support:

                                          Continuing Education (CME/CE) Support

                                          Loading Comments...